Molecular Partners AGMLLCF 25 EV-to-EBIT is -0.77 as of Jul. 09, 2026. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 366 Biotechnology companies, Molecular Partners AG ranks worse than 273223.77% on this metric.
Molecular Partners AG (OTCPK:MLLCF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Molecular Partners AG's Enterprise Value for the quarter that ended in Mar. 2026 was $-11.40 Mil.
Molecular Partners AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-72.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Molecular Partners AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's EV-to-EBIT falls into.
Molecular Partners AG's current Enterprise Value is $55.59 Mil.
Molecular Partners AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-72.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (MLLCF) has a EV-to-EBIT of -0.77 as of Jul. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Molecular Partners AG and its competitors. According to the industry distribution chart, Molecular Partners AG ranks #999999 out of 366 companies in the Biotechnology industry.
Is Molecular Partners AG's EV-to-EBIT too high?
Molecular Partners AG's current EV-to-EBIT is -0.77. Based on the distribution chart, Molecular Partners AG ranks #999999 out of 366 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #999999 out of 366 companies for EV-to-EBIT. This places Molecular Partners AG in the lower half of its industry. The industry median EV-to-EBIT is 14.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.63, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Molecular Partners AG and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current EV-to-EBIT is -0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $3.80 — trading 763.6% above its estimated fair value. The current EV-to-EBIT is -0.77. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current EV-to-EBIT is -0.77 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.80 is trading 763.6% above its estimated GF Value™ of $0.44.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
EV-to-EBIT: -0.77
GF Value™: $0.44 vs. price of $3.80 (763.6% above fair value)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score
Get the complete analysis for MLLCF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
